124
Participants
Start Date
August 2, 2017
Primary Completion Date
March 20, 2018
Study Completion Date
January 10, 2019
Botulinum toxin A (GSK1358820)
GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
Placebo
Placebo injection will contain sodium chloride (0.9 mg).
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Chiba
GSK Investigational Site, Fukui
GSK Investigational Site, Fukuoka
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hyōgo
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kochi
GSK Investigational Site, Kumamoto
GSK Investigational Site, Nagano
GSK Investigational Site, Niigata
GSK Investigational Site, Okayama
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Ōita
GSK Investigational Site, Saga
GSK Investigational Site, Shizuoka
GSK Investigational Site, Shizuoka
GSK Investigational Site, Tokushima
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Wakayama
GSK Investigational Site, Yamagata
Lead Sponsor
GlaxoSmithKline
INDUSTRY